RxDoctor Payments Data

Sunita Jain, MD

Internal Medicine · Sacramento, CANPI 1184691974

Payments from drug & device makers

$2,738in general payments, 2019–2025

Across 134 payments — averaging $20.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$506
  • AstraZeneca$327
  • Pfizer$249
  • Lilly USA, LLC$222
  • Merck$202
  • Boehringer Ingelheim$194
  • plus $1K from 18 others

What the payments were for

  • Food & beverage$2,738100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,738 in reported general payments places this provider in the 85th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$113,275
Medicare patients
314
Services billed
1,282

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban150$142,492
JanuviaSitagliptin Phosphate99$132,824
FarxigaDapagliflozin Propanediol63$65,167
OzempicSemaglutide52$61,324
JardianceEmpagliflozin53$55,362
TrulicityDulaglutide16$24,939
RybelsusSemaglutide15$24,547
Breo ElliptaFluticasone/Vilanterol18$12,142
LinzessLinaclotide15$10,700
Trelegy ElliptaFluticasone/Umeclidin/Vilanter16$10,431
Levothyroxine Sodium589$8,871
Pitavastatin Calcium15$7,004
Lantus SolostarInsulin Glargine,hum.Rec.Anlog39$5,933
Atorvastatin Calcium491$5,914
Gabapentin272$5,677

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Premarin$249$147,016161 claims
MerckJanuvia$202$132,82499 claims
Novo NordiskOzempic, Rybelsus$57$85,87167 claims
AstraZenecaFarxiga, Symbicort$327$69,02477 claims
Boehringer IngelheimJardiance$194$55,36253 claims
Lilly USA, LLCTrulicity, Humalog$222$26,95238 claims
GSKBreo Ellipta, Trelegy Ellipta$506$22,57334 claims
AbbVieLinzess, Synthroid$180$13,58861 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Sacramento

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →